Navigation Links
Drug shows promise for effectively treating metabolic syndrome
Date:7/3/2014

(SALT LAKE CITY)University of Utah researchers have discovered that an enzyme involved in intracellular signaling plays a crucial role in developing metabolic syndrome, a finding that has a U of U spinoff company developing a drug to potentially treat the condition.

The researchers, led by Jared Rutter, Ph.D., professor of biochemistry, hope to begin human clinical trials of a drug in the next couple of years.

"The approved drug therapies do not treat or prevent this condition in most people," says Rutter, senior author of a study describing the research published July 3, 2014, in Cell Reports. "But given the results of our research with mouse and rat models, we are hopeful that metabolic syndrome can be effectively treated with drug therapy someday soon."

Metabolic syndrome, a group of conditions that increases the risk for developing heart disease, diabetes and stroke, is estimated to affect up to 25 percent of adults. Public health officials believe metabolic syndrome has reached epidemic proportions in the United States and elsewhere.

Metabolic syndrome includes disorders such as high blood pressure, high blood sugar levels, abnormal cholesterol readings, and obesity. One of the prominent features of the syndrome is the excessive production and storage of fatty acids and triglycerides.

In research with rodents, Rutter, doctoral student and first author on the Cell Reports study Xiaoying Wu, and Allen Nickols of BioEnergenix, a company Rutter co-founded in 2009, discovered that an enzyme known as PASK stimulates the overproduction of fatty acids and triglycerides. PASK works by chemically modifying other proteins in order to alter their specific functions. One of the proteins it modifies is SREBP-1c, which functions as the master regulator of all of the enzymes that make fat.

Using a drug candidate being developed by the University of Utah spinoff company BioEnergenix, the researchers prevented PASK from modifying SREBP-1c. This, in turn, prevented SREBP-1c from increasing the production of enzymes that make fat, resulting in a drop in the levels of fatty acids and triglycerides in mouse and rat livers. Insulin resistance and diabetes were also partially reversed in diabetes-prone animals.

"We hope that this is an example where science leads us not only to a better understanding of how the body works, but also to the discovery of approaches that we can use to treat human disease," Rutter says.

Researchers don't know what causes fatty acids and triglycerides to be overproduced, and that will be a focus of Rutter's ongoing research as well as trying to understand how PASK activates SREBP-1c.

This study is a prime example of a public/private partnership to advance research and health care, a model becoming more common in medical and other scientific research. In this case, a U of U spinoff company is using a University of Utah-developed technology to improve the knowledge and clinical treatment of an issue with a major impact on U.S. health. To address this health issue, the University of Utah recently established the Center for Diabetes and Metabolism, which pairs researchers and clinicians who work side by side to develop treatment and prevention options. Rutter serves as co-director of this center.


'/>"/>

Contact: Phil Sahm
phil.sahm@hsc.utah.edu
801-581-2517
University of Utah Health Sciences
Source:Eurekalert

Related medicine news :

1. Fear, not data, motivates sunscreen users, research shows
2. New research study shows huge savings for health care
3. Penn study shows changing roles of physicians with MBAs
4. New research shows link unlikely between insomnia symptoms and high blood pressure
5. Study shows cost-effectiveness of smoking cessation counseling during hospitalization
6. Gut bacteria predict survival after stem cell transplant, study shows
7. New post-hoc analysis shows patients with type 2 diabetes undergoing intensification of insulin therapy experienced less nighttime hypoglycemia while being treated with Januvia (Sitagliptin) compared to placebo
8. Moffitt study shows utilizing genetic health care professional reduces unnecessary testing
9. Miriam Hospital study shows how to make statewide health campaigns more effective
10. MRI shows brain abnormalities in late preterm infants
11. Presurgical SPECT/CT shows more cancer than current standard
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2017)... Rockville, MD (PRWEB) , ... August 18, 2017 ... ... Food and Drug Administration Reauthorization Act of 2017, legislation that provides for greater ... perceived mild to moderate hearing loss to access OTC hearing aids without being ...
(Date:8/19/2017)... ... 19, 2017 , ... Curl Keeper® is excited to announce that the H2O ... 2017 Award for the second year in a row. The H2O Bottle, a refillable ... voted Best Moisturizer for Type 2 Wavies and Best Refresher for Type 2 Wavies ...
(Date:8/19/2017)... ... , ... Yesterday, the President of the United States retracted his condemnation of ... not two sides to hatred, bigotry, discrimination, and a white supremacy nationalist agenda. ... against all forms of such hatred and discrimination in this country and globally. ...
(Date:8/19/2017)... ... August 19, 2017 , ... ... has joined its Orlando location as an interventional pain management physician. He brings ... on the treatment of migraine headaches, and significant experience in spinal cord stimulation ...
(Date:8/18/2017)... Thailand (PRWEB) , ... August 19, 2017 , ... ... Business, Tourism Authority of Thailand presided over the Amazing Thailand Health and Wellness ... in Thailand. , Mr. Noppadon Pakprot, Deputy Governor for Tourism Products and Business ...
Breaking Medicine News(10 mins):
(Date:8/15/2017)... , Aug. 15, 2017   Mostyn Law and ... Houston, Texas . The Mostyn Law ... past 2 years. That is why Mostyn Law is ... to show its appreciation. Blood supplies are ... fall 5% short of hospital needs in August. That is why ...
(Date:8/14/2017)... and PETACH TIKVAH, Israel , ... BCLI), a leading developer of adult stem cell technologies ... quarter ending June 30, 2017. ... preparing for our pivotal Phase 3 trial to investigate ... , President and Chief Executive Officer of BrainStorm. "We ...
(Date:8/7/2017)... , Aug. 7, 2017 Insightin Health, ... acquisition, retention, and engagement, announced the selection of ... and Product Development, effective as of February 2017. In ... technology implementation strategy for our clients. Wood brings ... in consulting and business analytics within the healthcare ...
Breaking Medicine Technology: